BHIC (BioScience Health Innovations) Beneish M-Score: -1.33 (As of Jun. 26, 2026)


BHIC BioScience Health Innovations Inc BHIC
45 GF Score
Price $4.00
GF Value $164.84
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is BioScience Health Innovations Beneish M-Score?

BioScience Health Innovations BHIC -8.05% 45 Beneish M-Score is -1.33 as of Jun. 26, 2026. GuruFocus rates BHIC with a GF Score™ of 45/100 and a GF Value™ of $164.84 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 633 Healthcare Providers & Services companies, BioScience Health Innovations ranks worse than 89.42% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.33 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for BioScience Health Innovations's Beneish M-Score or its related term are showing as below:

BHIC' s Beneish M-Score Range Over the Past 10 Years
Min: -1.33   Med: -0.29   Max: 0.75
Current: -1.33

During the past 7 years, the highest Beneish M-Score of BioScience Health Innovations was 0.75. The lowest was -1.33. And the median was -0.29.


BioScience Health Innovations Beneish M-Score Historical Data

* Premium members only.

The historical data trend for BioScience Health Innovations's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioScience Health Innovations Beneish M-Score Chart

BioScience Health Innovations Annual Data
Trend Aug19 Aug20 Aug21 Aug22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.75

BioScience Health Innovations Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.75 -1.33

BHIC vs PETS, SHFH, SCNX: Beneish M-Score Comparison

For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioScience Health Innovations Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where BioScience Health Innovations's Beneish M-Score falls into.


BHIC
45GF Score
BioScience Health Innovations Inc BHIC
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioScience Health Innovations Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of BioScience Health Innovations for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4496+0.528 * 1.2985+0.404 * 0.9301+0.892 * 1.8654+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.058+4.679 * 0.297425-0.327 * 2.9035
=-1.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $0.08 Mil.
Revenue was 0.751 + 1.573 + 1.131 + 1.757 = $5.21 Mil.
Gross Profit was 0.486 + 0.572 + 0.698 + 1.074 = $2.83 Mil.
Total Current Assets was $2.20 Mil.
Total Assets was $2.33 Mil.
Property, Plant and Equipment(Net PPE) was $0.05 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $2.77 Mil.
Total Current Liabilities was $0.19 Mil.
Long-Term Debt & Capital Lease Obligation was $0.46 Mil.
Net Income was -0.23 + -0.234 + -0.009 + 0.458 = $-0.02 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -0.552 + -0.101 + -0.34 + 0.285 = $-0.71 Mil.
Total Receivables was $0.09 Mil.
Revenue was 1.227 + 0.61 + 0.573 + 0.384 = $2.79 Mil.
Gross Profit was 0.896 + 0.339 + 0.425 + 0.31 = $1.97 Mil.
Total Current Assets was $1.34 Mil.
Total Assets was $1.40 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $1.40 Mil.
Total Current Liabilities was $0.13 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.078 / 5.212) / (0.093 / 2.794)
=0.014965 / 0.033286
=0.4496

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.97 / 2.794) / (2.83 / 5.212)
=0.705082 / 0.542978
=1.2985

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2.195 + 0.048) / 2.33) / (1 - (1.339 + 0) / 1.395)
=0.037339 / 0.040143
=0.9301

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=5.212 / 2.794
=1.8654

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 0)) / (0 / (0 + 0.048))
= / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2.769 / 5.212) / (1.403 / 2.794)
=0.531274 / 0.502147
=1.058

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.46 + 0.185) / 2.33) / ((0 + 0.133) / 1.395)
=0.276824 / 0.095341
=2.9035

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-0.015 - 0 - -0.708) / 2.33
=0.297425

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

BioScience Health Innovations has a M-score of -1.33 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.33 mean?
BioScience Health Innovations (BHIC) has a Beneish M-Score of -1.33 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on BioScience Health Innovations and its competitors. According to the industry distribution chart, BioScience Health Innovations ranks #566 out of 633 companies in the Healthcare Providers & Services industry, placing it in the top 89.4%.
Is BioScience Health Innovations' Beneish M-Score too high?
BioScience Health Innovations' current Beneish M-Score is -1.33. Based on the distribution chart, BioScience Health Innovations ranks #566 out of 633 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, BioScience Health Innovations has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' Beneish M-Score compare to PETS and SHFH?
According to the Healthcare Providers & Services industry distribution chart, BioScience Health Innovations ranks #566 out of 633 companies for Beneish M-Score. This places BioScience Health Innovations in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on BioScience Health Innovations and its competitors. BioScience Health Innovations's current Beneish M-Score is -1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $164.84, compared to a current price of $4.00 — trading 97.6% below its estimated fair value. The current Beneish M-Score is -1.33. BioScience Health Innovations' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current Beneish M-Score is -1.33 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioScience Health Innovations (BHIC) Overvalued in 2026?

Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued. The current stock price of $4.00 is trading 97.6% below its estimated GF Value™ of $164.84. GuruFocus considers BioScience Health Innovations to be Possible Value Trap.

Key valuation signals for BHIC:

  • Beneish M-Score: -1.33
  • GF Value™: $164.84 vs. price of $4.00 (97.6% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioScience Health Innovations Business Description

Address 14857 South Concord Park Drive, Bluffdale, UT, USA, 84065
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
45GF Score

Get the complete analysis for BHIC

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.00
Price
$164.84
GF Value